Methylnaltrexone Bromide
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Methylnaltrexone Bromide |
| DrugBank ID | DB06800 |
| Brand Names (EU) | Relistor |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 78.35% |
Approved Indication (EMA)
Treatment of opioid-induced constipation in advanced-illness patients who are receiving palliative care when response to usual laxative therapy has not been sufficient.
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | congenital hypotrichosis milia | 78.35% | DL |
| 2 | hypotrichosis simplex of the scalp | 77.28% | DL |
| 3 | exercise-induced malignant hyperthermia | 76.59% | DL |
| 4 | common cold | 76.41% | DL |
| 5 | alopecia | 75.44% | DL |
| 6 | diffuse alopecia areata | 75.29% | DL |
| 7 | respiratory failure | 71.98% | DL |
| 8 | familial periodic paralysis | 71.31% | DL |
| 9 | obsolete hyperuricemia (disease) | 71.23% | DL |
| 10 | trigeminal autonomic cephalalgia | 67.58% | DL |
| 11 | adrenal gland pheochromocytoma | 67.22% | DL |
| 12 | benign neoplasm of adrenal medulla | 66.83% | DL |
| 13 | primary hereditary glaucoma | 66.72% | DL |
| 14 | headache disorder | 66.03% | DL |
| 15 | open-angle glaucoma | 65.48% | DL |
| 16 | hypokalemic periodic paralysis | 65.35% | DL |
| 17 | duodenum cancer | 63.26% | DL |
| 18 | adrenal medulla cancer | 63.01% | DL |
| 19 | sympathetic nervous system disease | 62.02% | DL |
| 20 | hypouricemia, renal | 61.74% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.